Cronos Group (CRON) Stock Price & Analysis
CRON Stock Chart & Stats
- Day’s Range
- $3.34 - $3.46
- 52-Week Range
- $2.28 - $3.61
- Previous Close
- $3.33
- Volume
- N/A
- Average Volume (3M)
- 886.47K
- Market Cap
- $1.24B
- Enterprise Value
- $410.50M
- Total Cash (Recent Filing)
- $797.02M
- Total Debt (Recent Filing)
- $1.29M
- Price to Earnings (P/E)
- 18.1
- Beta
- 0.54
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 0.03
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Operating Momentum
Strong recent growth is supported by a broader multi-year revenue rebound, rising from approximately $87.0M in 2023 to $179.0M TTM. This indicates improving demand and distribution, creating a stronger base for continued operating leverage over coming quarters.
Brand Strength And Market Position
Spinach’s category leadership across several high-value product formats provides evidence of meaningful brand traction rather than growth from one isolated product. Sustained share positions can support repeat purchases, distribution strength and resilience against cannabis-market competition.
Conservative Balance Sheet And Improved Cash Generation
Minimal leverage and positive operating and free cash flow give Cronos substantial financial flexibility to fund growth, absorb industry volatility and pursue opportunities without relying heavily on external financing. This strengthens the company’s durability as profitability develops.
Bears Say
Profitability Remains Inconsistent
The operating turnaround is encouraging, but negative TTM net margin and the recent history of losses show that earnings durability has not yet been established. Continued execution is required before revenue growth can reliably translate into sustained bottom-line profitability.
Gross Margin Variability
Margin expansion has benefited from favorable growing conditions and mix, so reported profitability may fluctuate as those factors change. Variable margins make earnings less predictable and could weaken cash conversion if pricing, product mix or seasonal conditions become less favorable.
Regulatory Risk In Israel
The investigation affects a strategically important growth market where Cronos Israel has delivered repeated record quarters. Potential regulatory action could disrupt market access, pricing or product flows, making the company’s international growth trajectory less certain.
Cronos Group News
CRON FAQ
What was Cronos Group’s price range in the past 12 months?
What is Cronos Group’s market cap?
When is Cronos Group’s upcoming earnings report date?
How were Cronos Group’s earnings last quarter?
Is Cronos Group overvalued?
Does Cronos Group pay dividends?
What is Cronos Group’s EPS estimate?
How many shares outstanding does Cronos Group have?
What happened to Cronos Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cronos Group?
What is the TipRanks Smart Score and how is it calculated?
Cronos Group Stock Smart Score
Company Description
Cronos Group
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under its Lord Jones and Happy Dance brands through online sales, traditional retail, and hospitality partner networks. The company also plays a significant role in the cultivation, production, and commercialization of cannabis and cannabis-infused products for both medicinal and adult-use sectors. Its comprehensive product offerings encompass dried cannabis flower, pre-rolled joints, edibles, concentrated forms, and cannabis extracts. These are distributed via wholesale partnerships and direct-to-consumer channels, prominently featuring its wellness platform, PEACE NATURALS, and its adult-use brand, Spinach. Moreover, Cronos Group exports dried cannabis and cannabis oils to international markets including Germany, Israel, and Australia. Established in 2012, the company maintains its corporate headquarters in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Michael Ryan Gorenstein
- Employees
- 610
- Website
- www.thecronosgroup.com
- Address
- 4491 Concession Road 12, Stayner, ON, L0M 1S0, CA
Cronos Group (CRON) Earnings & Revenues
CRON Earnings Call
Earnings Call SentimentPositive
The call conveyed a broadly positive operational and financial picture: record revenue, gross profit, and adjusted EBITDA, strong brand performance (notably Spinach), meaningful international growth (Israel and Germany), and a robust cash position. Key risks and headwinds include a new anti-dumping investigation in Israel, modest OpEx increases, margin variability tied to seasonality and mix, and timing uncertainty around the CanAdelaar closing. On balance, the positive operational momentum and strong financials outweigh the highlighted risks.
View all CRON earnings summariesCRON Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 4 | 2 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 12 | 0 | 0 |











